+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Longevity and Anti-senescence Therapy Market By Therapy, By Application, By End user: Global Opportunity Analysis and Industry Forecast, 2020-2030

  • PDF Icon

    Report

  • 200 Pages
  • March 2022
  • Region: Global
  • Allied Market Research
  • ID: 5640389
Description Jump to:
The global longevity and anti-senescence therapy market was valued at $25,087.3 million in 2020, and is projected to reach $44,234.8 million by 2030, registering a CAGR of 6.1% from 2021 to 2030.

Aging is marked by a progressive loss of physiological integrity and function over time. Aging epigenetics refers to the changes in gene expression that occur naturally during a lifespan of the organism without changing the DNA sequence. Several enzymes are involved in chromatin epigenetics, which result in changes in DNA methylation and histone methylation/acetylation processes. Chromatin appears to be more active during ageing, resulting in more relaxed global gene expression with an overall decrease in DNA methylation. Senescent cells are linked with many age-related diseases such as cataract, glaucoma, neurodegenerative diseases (Alzheimer and Parkinson), cardiovascular diseases (CVD, atherosclerosis, and hypertension), idiopathic pulmonary fibrosis (IPF), diabetes type II, sarcopenia, osteoarthritis, osteoporosis, chronic obstructive pulmonary disease (COPD), and certain types of tumors.

Increase in prevalence of chronic diseases, rise in awareness about anti-aging products, and advancements in AI driven medical technology drive the growth of the market. Moreover, increase in geriatric population and increase in demand for personalized, precise, preventive, and participatory aging treatments contribute toward the growth of the market. However, dearth of skilled professionals and loss of tissue-repair capacity are the major barriers that hinder the growth of the market. Conversely, increase in demand for cell-based assays in R&D are expected to offer lucrative growth opportunities for market during the forecast period.

The global longevity and anti-senescence therapy market is segmented on the basis of therapy, application, end user and region. Depending on therapy, it is categorized into senolytic drug therapy, gene therapy and immunotherapy. On the basis of application, the market is classified as cancer and others. According to end user, it is classified into hospitals and medical service institution. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include AgeX Therapeutics Inc., Bristol-Myers Squibb Company, Calico Life Sciences LLC, CohBar, Inc., Life Biosciences, Inc., Merck & Co. Inc., Oisin Biotechnologies, Pfizer, Inc., T.A. Sciences, Inc., Unity Biotechnology, Inc.

Key Benefits For Stakeholders

  • This report provides a detailed - Quantitative analysis of the current market trends and future estimations from 2020 to 2030, which assists to identify the prevailing market opportunities.
  • An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
  • A comprehensive analysis of the factors that drive and restrain the growth of the longevity and anti-senescence therapy market is provided.
  • An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

Key Market Segments


By THERAPY

  • Senolytic Drug Therapy
  • Gene Therapy
  • Immunotherapy

By APPLICATION

  • Cancer
  • Others

By END USER

  • Hospitals
  • Medical Service Institution

By REGION

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Ital
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Turkey
  • South Africa
  • Rest of LAMEA

KEY MARKET PLAYERS

  • AgeX Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Calico Life Sciences LLC
  • CohBar, Inc.
  • Life Biosciences, Inc.
  • Merck & Co. Inc.
  • Oisin Biotechnologies
  • Pfizer, Inc.
  • T.A. Sciences, Inc.
  • Unity Biotechnology, Inc.

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market
CHAPTER 4: LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY THERAPY
4.1 Overview
4.1.1 Market size and forecast
4.2 Senolytic Drug Therapy
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Gene Therapy
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Immunotherapy
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
CHAPTER 5: LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY APPLICATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Cancer
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Others
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
CHAPTER 6: LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY END USER
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Medical Service Institution
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
CHAPTER 7: LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 LAMEA
7.2.1 Key trends and opportunities
7.2.2 LAMEA Market size and forecast, by Therapy
7.2.3 LAMEA Market size and forecast, by Application
7.2.4 LAMEA Market size and forecast, by End user
7.2.5 LAMEA Market size and forecast, by country
7.2.5.1 Brazil
7.2.5.1.1 Market size and forecast, by Therapy
7.2.5.1.2 Market size and forecast, by Application
7.2.5.1.3 Market size and forecast, by End user
7.2.5.2 Turkey
7.2.5.2.1 Market size and forecast, by Therapy
7.2.5.2.2 Market size and forecast, by Application
7.2.5.2.3 Market size and forecast, by End user
7.2.5.3 South Africa
7.2.5.3.1 Market size and forecast, by Therapy
7.2.5.3.2 Market size and forecast, by Application
7.2.5.3.3 Market size and forecast, by End user
7.2.5.4 Rest of LAMEA
7.2.5.4.1 Market size and forecast, by Therapy
7.2.5.4.2 Market size and forecast, by Application
7.2.5.4.3 Market size and forecast, by End user
7.3 North America
7.3.1 Key trends and opportunities
7.3.2 North America Market size and forecast, by Therapy
7.3.3 North America Market size and forecast, by Application
7.3.4 North America Market size and forecast, by End user
7.3.5 North America Market size and forecast, by country
7.3.5.1 U.S.
7.3.5.1.1 Market size and forecast, by Therapy
7.3.5.1.2 Market size and forecast, by Application
7.3.5.1.3 Market size and forecast, by End user
7.3.5.2 Canada
7.3.5.2.1 Market size and forecast, by Therapy
7.3.5.2.2 Market size and forecast, by Application
7.3.5.2.3 Market size and forecast, by End user
7.3.5.3 Mexico
7.3.5.3.1 Market size and forecast, by Therapy
7.3.5.3.2 Market size and forecast, by Application
7.3.5.3.3 Market size and forecast, by End user
7.4 Europe
7.4.1 Key trends and opportunities
7.4.2 Europe Market size and forecast, by Therapy
7.4.3 Europe Market size and forecast, by Application
7.4.4 Europe Market size and forecast, by End user
7.4.5 Europe Market size and forecast, by country
7.4.5.1 Germany
7.4.5.1.1 Market size and forecast, by Therapy
7.4.5.1.2 Market size and forecast, by Application
7.4.5.1.3 Market size and forecast, by End user
7.4.5.2 France
7.4.5.2.1 Market size and forecast, by Therapy
7.4.5.2.2 Market size and forecast, by Application
7.4.5.2.3 Market size and forecast, by End user
7.4.5.3 United Kingdom
7.4.5.3.1 Market size and forecast, by Therapy
7.4.5.3.2 Market size and forecast, by Application
7.4.5.3.3 Market size and forecast, by End user
7.4.5.4 Italy
7.4.5.4.1 Market size and forecast, by Therapy
7.4.5.4.2 Market size and forecast, by Application
7.4.5.4.3 Market size and forecast, by End user
7.4.5.5 Rest of Europe
7.4.5.5.1 Market size and forecast, by Therapy
7.4.5.5.2 Market size and forecast, by Application
7.4.5.5.3 Market size and forecast, by End user
7.5 Asia-Pacific
7.5.1 Key trends and opportunities
7.5.2 Asia-Pacific Market size and forecast, by Therapy
7.5.3 Asia-Pacific Market size and forecast, by Application
7.5.4 Asia-Pacific Market size and forecast, by End user
7.5.5 Asia-Pacific Market size and forecast, by country
7.5.5.1 Japan
7.5.5.1.1 Market size and forecast, by Therapy
7.5.5.1.2 Market size and forecast, by Application
7.5.5.1.3 Market size and forecast, by End user
7.5.5.2 China
7.5.5.2.1 Market size and forecast, by Therapy
7.5.5.2.2 Market size and forecast, by Application
7.5.5.2.3 Market size and forecast, by End user
7.5.5.3 Australia
7.5.5.3.1 Market size and forecast, by Therapy
7.5.5.3.2 Market size and forecast, by Application
7.5.5.3.3 Market size and forecast, by End user
7.5.5.4 India
7.5.5.4.1 Market size and forecast, by Therapy
7.5.5.4.2 Market size and forecast, by Application
7.5.5.4.3 Market size and forecast, by End user
7.5.5.5 Rest of Asia-Pacific
7.5.5.5.1 Market size and forecast, by Therapy
7.5.5.5.2 Market size and forecast, by Application
7.5.5.5.3 Market size and forecast, by End user
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 AgeX Therapeutics, Inc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Bristol-Myers Squibb Company
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Calico Life Sciences LLC
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 CohBar, Inc.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Life Biosciences, Inc.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Merck & Co., Inc.
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Oisin Biotechnologies
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Pfizer Inc.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 T.A. Sciences, Inc.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Unity Biotechnology, Inc.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
LIST OF TABLES
Table 1. Global Longevity and Anti-Senescence Therapy Market, by Therapy, 2020-2030, ($Million)
Table 2. Longevity and Anti-Senescence Therapy Market Revenue, for Senolytic Drug Therapy, by Region, 2020-2030, ($Million)
Table 3. Longevity and Anti-Senescence Therapy Market Senolytic Drug Therapy by Country, 2020-2030, ($Million)
Table 4. Longevity and Anti-Senescence Therapy Market Revenue, for Gene Therapy, by Region, 2020-2030, ($Million)
Table 5. Longevity and Anti-Senescence Therapy Market Gene Therapy by Country, 2020-2030, ($Million)
Table 6. Longevity and Anti-Senescence Therapy Market Revenue, for Immunotherapy, by Region, 2020-2030, ($Million)
Table 7. Longevity and Anti-Senescence Therapy Market Immunotherapy by Country, 2020-2030, ($Million)
Table 8. Global Longevity and Anti-Senescence Therapy Market, by Application, 2020-2030, ($Million)
Table 9. Longevity and Anti-Senescence Therapy Market Revenue, for Cancer, by Region, 2020-2030, ($Million)
Table 10. Longevity and Anti-Senescence Therapy Market Cancer by Country, 2020-2030, ($Million)
Table 11. Longevity and Anti-Senescence Therapy Market Revenue, for Others, by Region, 2020-2030, ($Million)
Table 12. Longevity and Anti-Senescence Therapy Market Others by Country, 2020-2030, ($Million)
Table 13. Global Longevity and Anti-Senescence Therapy Market, by End-user, 2020-2030, ($Million)
Table 14. Longevity and Anti-Senescence Therapy Market Revenue, for Hospital, by Region, 2020-2030, ($Million)
Table 15. Longevity and Anti-Senescence Therapy Market Hospital by Country, 2020-2030, ($Million)
Table 16. Longevity and Anti-Senescence Therapy Market Revenue, for Medical Service Institution, by Region, 2020-2030, ($Million)
Table 17. Longevity and Anti-Senescence Therapy Market Medical Service Institution by Country, 2020-2030, ($Million)
Table 18. Longevity and Anti-Senescence Therapy Market, by Region, 2020-2030, ($Million)
Table 19. LAMEA Longevity and Anti-Senescence Therapy Market, by Therapy, 2020-2030, ($Million)
Table 20. LAMEA Longevity and Anti-Senescence Therapy Market, by Application, 2020-2030, ($Million)
Table 21. LAMEA Longevity and Anti-Senescence Therapy Market, by End-user, 2020-2030, ($Million)
Table 22. LAMEA Longevity and Anti-Senescence Therapy Market, by Country, 2020-2030, ($Million)
Table 23. Brazil Longevity and Anti-Senescence Therapy Market by Therapy 2020-2030, ($Million)
Table 24. Brazil Longevity and Anti-Senescence Therapy Market by Application 2020-2030, ($Million)
Table 25. Brazil Longevity and Anti-Senescence Therapy Market by End-user 2020-2030, ($Million)
Table 26. Turkey Longevity and Anti-Senescence Therapy Market by Therapy 2020-2030, ($Million)
Table 27. Turkey Longevity and Anti-Senescence Therapy Market by Application 2020-2030, ($Million)
Table 28. Turkey Longevity and Anti-Senescence Therapy Market by End-user 2020-2030, ($Million)
Table 29. South Africa Longevity and Anti-Senescence Therapy Market by Therapy 2020-2030, ($Million)
Table 30. South Africa Longevity and Anti-Senescence Therapy Market by Application 2020-2030, ($Million)
Table 31. South Africa Longevity and Anti-Senescence Therapy Market by End-user 2020-2030, ($Million)
Table 32. Rest of LAMEA Longevity and Anti-Senescence Therapy Market by Therapy 2020-2030, ($Million)
Table 33. Rest of LAMEA Longevity and Anti-Senescence Therapy Market by Application 2020-2030, ($Million)
Table 34. Rest of LAMEA Longevity and Anti-Senescence Therapy Market by End-user 2020-2030, ($Million)
Table 35. North America Longevity and Anti-Senescence Therapy Market, by Therapy, 2020-2030, ($Million)
Table 36. North America Longevity and Anti-Senescence Therapy Market, by Application, 2020-2030, ($Million)
Table 37. North America Longevity and Anti-Senescence Therapy Market, by End-user, 2020-2030, ($Million)
Table 38. North America Longevity and Anti-Senescence Therapy Market, by Country, 2020-2030, ($Million)
Table 39. U.S. Longevity and Anti-Senescence Therapy Market by Therapy 2020-2030, ($Million)
Table 40. U.S. Longevity and Anti-Senescence Therapy Market by Application 2020-2030, ($Million)
Table 41. U.S. Longevity and Anti-Senescence Therapy Market by End-user 2020-2030, ($Million)
Table 42. Canada Longevity and Anti-Senescence Therapy Market by Therapy 2020-2030, ($Million)
Table 43. Canada Longevity and Anti-Senescence Therapy Market by Application 2020-2030, ($Million)
Table 44. Canada Longevity and Anti-Senescence Therapy Market by End-user 2020-2030, ($Million)
Table 45. Mexico Longevity and Anti-Senescence Therapy Market by Therapy 2020-2030, ($Million)
Table 46. Mexico Longevity and Anti-Senescence Therapy Market by Application 2020-2030, ($Million)
Table 47. Mexico Longevity and Anti-Senescence Therapy Market by End-user 2020-2030, ($Million)
Table 48. Europe Longevity and Anti-Senescence Therapy Market, by Therapy, 2020-2030, ($Million)
Table 49. Europe Longevity and Anti-Senescence Therapy Market, by Application, 2020-2030, ($Million)
Table 50. Europe Longevity and Anti-Senescence Therapy Market, by End-user, 2020-2030, ($Million)
Table 51. Europe Longevity and Anti-Senescence Therapy Market, by Country, 2020-2030, ($Million)
Table 52. Germany Longevity and Anti-Senescence Therapy Market by Therapy 2020-2030, ($Million)
Table 53. Germany Longevity and Anti-Senescence Therapy Market by Application 2020-2030, ($Million)
Table 54. Germany Longevity and Anti-Senescence Therapy Market by End-user 2020-2030, ($Million)
Table 55. France Longevity and Anti-Senescence Therapy Market by Therapy 2020-2030, ($Million)
Table 56. France Longevity and Anti-Senescence Therapy Market by Application 2020-2030, ($Million)
Table 57. France Longevity and Anti-Senescence Therapy Market by End-user 2020-2030, ($Million)
Table 58. United Kingdom Longevity and Anti-Senescence Therapy Market by Therapy 2020-2030, ($Million)
Table 59. United Kingdom Longevity and Anti-Senescence Therapy Market by Application 2020-2030, ($Million)
Table 60. United Kingdom Longevity and Anti-Senescence Therapy Market by End-user 2020-2030, ($Million)
Table 61. Italy Longevity and Anti-Senescence Therapy Market by Therapy 2020-2030, ($Million)
Table 62. Italy Longevity and Anti-Senescence Therapy Market by Application 2020-2030, ($Million)
Table 63. Italy Longevity and Anti-Senescence Therapy Market by End-user 2020-2030, ($Million)
Table 64. Rest of Europe Longevity and Anti-Senescence Therapy Market by Therapy 2020-2030, ($Million)
Table 65. Rest of Europe Longevity and Anti-Senescence Therapy Market by Application 2020-2030, ($Million)
Table 66. Rest of Europe Longevity and Anti-Senescence Therapy Market by End-user 2020-2030, ($Million)
Table 67. Asia-Pacific Longevity and Anti-Senescence Therapy Market, by Therapy, 2020-2030, ($Million)
Table 68. Asia-Pacific Longevity and Anti-Senescence Therapy Market, by Application, 2020-2030, ($Million)
Table 69. Asia-Pacific Longevity and Anti-Senescence Therapy Market, by End-user, 2020-2030, ($Million)
Table 70. Asia-Pacific Longevity and Anti-Senescence Therapy Market, by Country, 2020-2030, ($Million)
Table 71. Japan Longevity and Anti-Senescence Therapy Market by Therapy 2020-2030, ($Million)
Table 72. Japan Longevity and Anti-Senescence Therapy Market by Application 2020-2030, ($Million)
Table 73. Japan Longevity and Anti-Senescence Therapy Market by End-user 2020-2030, ($Million)
Table 74. China Longevity and Anti-Senescence Therapy Market by Therapy 2020-2030, ($Million)
Table 75. China Longevity and Anti-Senescence Therapy Market by Application 2020-2030, ($Million)
Table 76. China Longevity and Anti-Senescence Therapy Market by End-user 2020-2030, ($Million)
Table 77. Australia Longevity and Anti-Senescence Therapy Market by Therapy 2020-2030, ($Million)
Table 78. Australia Longevity and Anti-Senescence Therapy Market by Application 2020-2030, ($Million)
Table 79. Australia Longevity and Anti-Senescence Therapy Market by End-user 2020-2030, ($Million)
Table 80. India Longevity and Anti-Senescence Therapy Market by Therapy 2020-2030, ($Million)
Table 81. India Longevity and Anti-Senescence Therapy Market by Application 2020-2030, ($Million)
Table 82. India Longevity and Anti-Senescence Therapy Market by End-user 2020-2030, ($Million)
Table 83. Rest of Asia-Pacific Longevity and Anti-Senescence Therapy Market by Therapy 2020-2030, ($Million)
Table 84. Rest of Asia-Pacific Longevity and Anti-Senescence Therapy Market by Application 2020-2030, ($Million)
Table 85. Rest of Asia-Pacific Longevity and Anti-Senescence Therapy Market by End-user 2020-2030, ($Million)
Table 86. Agex Therapeutics, Inc.: Company Snapshot
Table 87. Agex Therapeutics, Inc.: Operating Segments
Table 88. Agex Therapeutics, Inc.: Product Portfolio
Table 89. Agex Therapeutics, Inc.: Net Sales
Table 90. Agex Therapeutics, Inc.: Key Stratergies
Table 91. Bristol-Myers Squibb Company: Company Snapshot
Table 92. Bristol-Myers Squibb Company: Operating Segments
Table 93. Bristol-Myers Squibb Company: Product Portfolio
Table 94. Bristol-Myers Squibb Company: Net Sales
Table 95. Bristol-Myers Squibb Company: Key Stratergies
Table 96. Calico Life Sciences LLC: Company Snapshot
Table 97. Calico Life Sciences LLC: Operating Segments
Table 98. Calico Life Sciences LLC: Product Portfolio
Table 99. Calico Life Sciences LLC: Net Sales
Table 100. Calico Life Sciences LLC: Key Stratergies
Table 101. Cohbar, Inc.: Company Snapshot
Table 102. Cohbar, Inc.: Operating Segments
Table 103. Cohbar, Inc.: Product Portfolio
Table 104. Cohbar, Inc.: Net Sales
Table 105. Cohbar, Inc.: Key Stratergies
Table 106. Life Biosciences, Inc.: Company Snapshot
Table 107. Life Biosciences, Inc.: Operating Segments
Table 108. Life Biosciences, Inc.: Product Portfolio
Table 109. Life Biosciences, Inc.: Net Sales
Table 110. Life Biosciences, Inc.: Key Stratergies
Table 111. Merck & Co., Inc.: Company Snapshot
Table 112. Merck & Co., Inc.: Operating Segments
Table 113. Merck & Co., Inc.: Product Portfolio
Table 114. Merck & Co., Inc.: Net Sales
Table 115. Merck & Co., Inc.: Key Stratergies
Table 116. Oisin Biotechnologies: Company Snapshot
Table 117. Oisin Biotechnologies: Operating Segments
Table 118. Oisin Biotechnologies: Product Portfolio
Table 119. Oisin Biotechnologies: Net Sales
Table 120. Oisin Biotechnologies: Key Stratergies
Table 121. Pfizer Inc.: Company Snapshot
Table 122. Pfizer Inc.: Operating Segments
Table 123. Pfizer Inc.: Product Portfolio
Table 124. Pfizer Inc.: Net Sales
Table 125. Pfizer Inc.: Key Stratergies
Table 126. T.A. Sciences, Inc.: Company Snapshot
Table 127. T.A. Sciences, Inc.: Operating Segments
Table 128. T.A. Sciences, Inc.: Product Portfolio
Table 129. T.A. Sciences, Inc.: Net Sales
Table 130. T.A. Sciences, Inc.: Key Stratergies
Table 131. Unity Biotechnology, Inc.: Company Snapshot
Table 132. Unity Biotechnology, Inc.: Operating Segments
Table 133. Unity Biotechnology, Inc.: Product Portfolio
Table 134. Unity Biotechnology, Inc.: Net Sales
Table 135. Unity Biotechnology, Inc.: Key Stratergies
LIST OF FIGURES
Figure 1. Longevity and Anti-Senescence Therapy Market Segmentation
Figure 2. Longevity and Anti-Senescence Therapy Market, 2020-2030
Figure 3. Longevity and Anti-Senescence Therapy Market, 2020-2030
Figure 4. Top Investment Pockets, by Region
Figure 5. Porter Five-1
Figure 6. Porter Five-2
Figure 7. Porter Five-3
Figure 8. Porter Five-4
Figure 9. Porter Five-5
Figure 10. Top Player Positioning
Figure 11. Longevity and Anti-Senescence Therapy Market:Drivers, Restraints and Opportunities
Figure 11. Longevity and Anti-Senescence Therapy Market, by Therapy, 2020 (%)
Figure 12. Comparative Share Analysis of Senolytic Drug Therapy Longevity and Anti-Senescence Therapy Market, 2020-2030 (%)
Figure 13. Comparative Share Analysis of Gene Therapy Longevity and Anti-Senescence Therapy Market, 2020-2030 (%)
Figure 14. Comparative Share Analysis of Immunotherapy Longevity and Anti-Senescence Therapy Market, 2020-2030 (%)
Figure 15. Longevity and Anti-Senescence Therapy Market, by Application, 2020 (%)
Figure 16. Comparative Share Analysis of Cancer Longevity and Anti-Senescence Therapy Market, 2020-2030 (%)
Figure 17. Comparative Share Analysis of Others Longevity and Anti-Senescence Therapy Market, 2020-2030 (%)
Figure 18. Longevity and Anti-Senescence Therapy Market, by End-user, 2020 (%)
Figure 19. Comparative Share Analysis of Hospital Longevity and Anti-Senescence Therapy Market, 2020-2030 (%)
Figure 20. Comparative Share Analysis of Medical Service Institution Longevity and Anti-Senescence Therapy Market, 2020-2030 (%)
Figure 21. Longevity and Anti-Senescence Therapy Market by Region, 2020
Figure 22. Brazil Longevity and Anti-Senescence Therapy Market, 2020-2030 ($Million)
Figure 23. Turkey Longevity and Anti-Senescence Therapy Market, 2020-2030 ($Million)
Figure 24. South Africa Longevity and Anti-Senescence Therapy Market, 2020-2030 ($Million)
Figure 25. Rest of LAMEA Longevity and Anti-Senescence Therapy Market, 2020-2030 ($Million)
Figure 26. U.S. Longevity and Anti-Senescence Therapy Market, 2020-2030 ($Million)
Figure 27. Canada Longevity and Anti-Senescence Therapy Market, 2020-2030 ($Million)
Figure 28. Mexico Longevity and Anti-Senescence Therapy Market, 2020-2030 ($Million)
Figure 29. Germany Longevity and Anti-Senescence Therapy Market, 2020-2030 ($Million)
Figure 30. France Longevity and Anti-Senescence Therapy Market, 2020-2030 ($Million)
Figure 31. United Kingdom Longevity and Anti-Senescence Therapy Market, 2020-2030 ($Million)
Figure 32. Italy Longevity and Anti-Senescence Therapy Market, 2020-2030 ($Million)
Figure 33. Rest of Europe Longevity and Anti-Senescence Therapy Market, 2020-2030 ($Million)
Figure 34. Japan Longevity and Anti-Senescence Therapy Market, 2020-2030 ($Million)
Figure 35. China Longevity and Anti-Senescence Therapy Market, 2020-2030 ($Million)
Figure 36. Australia Longevity and Anti-Senescence Therapy Market, 2020-2030 ($Million)
Figure 37. India Longevity and Anti-Senescence Therapy Market, 2020-2030 ($Million)
Figure 38. Rest of Asia-Pacific Longevity and Anti-Senescence Therapy Market, 2020-2030 ($Million)
Figure 39. Top Winning Strategies, by Year
Figure 40. Top Winning Strategies, by Development
Figure 41. Top Winning Strategies, by Company
Figure 42. Product Mapping of Top 10 Players
Figure 43. Competitive Dashboard
Figure 44. Competitive Heatmap of Top 10 Key Players
Figure 45. Agex Therapeutics, Inc. Net Sales, ($Million)
Figure 46. Bristol-Myers Squibb Company.: Net Sales, ($Million)
Figure 47. Calico Life Sciences LLC.: Net Sales, ($Million)
Figure 48. Cohbar, Inc. Net Sales, ($Million)
Figure 49. Life Biosciences, Inc. Net Sales, ($Million)
Figure 50. Merck & Co. Inc. Net Sales, ($Million)
Figure 51. Oisin Biotechnologies.: Net Sales, ($Million)
Figure 52. Pfizer Inc. Net Sales, ($Million)
Figure 53. T.A. Sciences, Inc. Net Sales, ($Million)
Figure 54. Unity Biotechnology, Inc. Net Sales, ($Million)

Executive Summary

The longevity and anti-senescence therapy market size was valued at $25.1 billion in 2020, and is estimated to reach $44.2 billion by 2030, growing at a CAGR of 6.1% from 2021 to 2030. Longevity is understood as a by-product of genes selected for their contribution in helping the organism to survive with enhanced life expectancy. The anti-aging research refers to slowing, preventing, or reversing the aging process. The molecular mechanisms accounting for the development of senescent-associated secretory phenotype (SASP) and the ones providing senescent cells maintenance supplied insights for the development of mechanisms to target senescent cells. Various approaches have been proposed to target cell senescence, either by inducing the death of senescent cells or by blocking the SASP.

The major factors that drive the growth of longevity and anti-senescence therapy market share are increase in prevalence of chronic diseases, rise in awareness about anti-aging products, and advancements in AI driven medical technology. Moreover, increase in geriatric population and increase in demand for personalized, precise, preventive, and participatory aging treatments contribute toward the growth of the market. However, dearth of skilled professionals and loss of tissue-repair capacity restrain the market growth during the forecast period. Conversely, increase in demand for cell-based assays in R&D are expected to offer lucrative growth opportunities for the market.

Coronavirus (COVID-19) was discovered in late December in Hubei province of Wuhan city in China. The disease is caused by a virus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted among humans. Amidst the initial outbreak of COVID-19, number of patients to undergo implant surgery declined, owing to the fear of infection during pandemic. Moreover, the demand for the antiaging treatment products was reduced. The production plants of the antiaging products were shut down during the lockdown imposed by the governments across the globe. In addition, lockdown created a financial crisis among the market players. This led to disturbances in import and export of anti-aging products across the countries. It was slightly positive amid the COVID-19 pandemic with an increase observed in prevalence of cardiovascular diseases, neural degenerative diseases, ophthalmology disorders, and cancer. For instance, according to data by the American Heart Association, in 2020, average person in the U.S. has a stroke every 40 seconds, accounting for one out of every 19 deaths. Overall, COVID-19 negatively impacted the longevity and anti-senescence therapy market. This was attributed to decrease in demand for anti-aging treatment products. Moreover, market players reduced investment in raw materials and resources, owing to decrease in number of hospital admissions of patients to undergo antiaging treatment.

The global longevity and anti-senescence therapy market size is segmented on the basis of therapy, application, end user and region. Depending on therapy, it is categorized into senolytic drug therapy, gene therapy and immunotherapy. On the basis of application, the market is classified as cancer and others. According to end user, it is classified into hospitals and medical service institution. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Depending on therapy, the longevity market is classified as senolytic drug therapy, gene therapy and immunotherapy. Gene therapy segment dominated the market in 2020, and is anticipated to remain dominant during the forecast period, due to increase in spread of awareness about longevity and antisenescence therapy, rise in prevalence of the chronic diseases, and effective product launches.

Depending on application, the Longevity and anti-senescence therapy market analysis is classified as cancer and others. Cancer segment dominated the market in 2020, and is anticipated to remain dominant during the forecast period, due to rise in demand for antiaging products and rise in disposable income.

According to end user, the longevity market is classified as hospitals and medical service institution. Hospitals dominated the market in 2020, and is anticipated to remain dominant during the forecast period, due to high usage of anti-aging products in hospitals for chronic diseases and advancements in AI driven medical technology.

North America dominated the longevity and anti-senescence therapy industry in 2020, and is expected to remain dominant throughout the forecast period. This is attributed to increase in incidence of chronic heart diseases, surge in demand for anti-aging products, rise in availability of advanced healthcare facilities with trained medical professionals, surge in number of R&D activities along with presence of key players, and growth in government investments in the healthcare system. However, Asia-Pacific is expected to experience highest growth rate during the forecast period. Moreover, Japan and China are expected to grow at the highest CAGR in Asia-Pacific, due to improvement in healthcare infrastructure, rise in number of hospitals equipped with advanced instruments, development of the R&D sector, rise in healthcare reforms, and technological advancements in the field of longevity and anti-senescence.

According to Onkar Sumant, Manager, Healthcare, 'Factors that drive the growth of the global longevity and anti-senescence therapy market include increase in prevalence of chronic diseases, rise in awareness about anti-aging products, and advancements in AI driven medical technology. However, the dearth of skilled professionals and loss of tissue-repair capacity are expected to hinder the market growth during the forecast period. Conversely, increase in demand for cell-based assays in R&D are expected to offer lucrative growth opportunities for the market.'

Key findings of the Study

  • Depending on therapy, the gene therapy segment held majority share in the global longevity and anti-senescence therapy market forecast in 2020.
  • Depending on application, the cancer segment held majority share in the global market in 2020.
  • According to end user, the hospitals segment held majority share in the global market in 2020.
  • Region wise, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 6.9% during the forecast period.

Companies Mentioned

  • AgeX Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Calico Life Sciences LLC
  • CohBar, Inc.
  • Life Biosciences, Inc.
  • Merck & Co., Inc.
  • Oisin Biotechnologies
  • Pfizer Inc.
  • T.A. Sciences, Inc.
  • Unity Biotechnology, Inc.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages200
PublishedMarch 2022
Forecast Period2020 - 2030
Estimated Market Value ( USD ) in 2020 $ 25087.3 million
Forecasted Market Value ( USD ) by 2030 $ 44234.8 million
Compound Annual Growth Rate5.8%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Treating Neurodegenerative Diseases as Metabolic Diseases. International Review of Neurobiology Volume 155 - Product Image

Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Treating Neurodegenerative Diseases as Metabolic Diseases. International Review of Neurobiology Volume 155

  • Book
  • Global
CNS Therapeutics - Global Strategic Business Report - Product Image

CNS Therapeutics - Global Strategic Business Report

  • Report
  • 898 Pages
  • Global
From
Myasthenia Gravis - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Myasthenia Gravis - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 287 Pages
  • Global
From
Anti-Epileptic Drugs/Epilepsy - Pipeline Insight, 2024 - Product Image

Anti-Epileptic Drugs/Epilepsy - Pipeline Insight, 2024

  • Drug Pipelines
  • 60 Pages
  • Global
From
Global Anti-Epileptic Drugs Market: Analysis By Drug Generation, By Distribution Channel, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2028 - Product Image

Global Anti-Epileptic Drugs Market: Analysis By Drug Generation, By Distribution Channel, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2028

  • Report
  • 159 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.